Publications by authors named "Christopher Hoimes"

Claim this Profile
E
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Cindy Y Jiang, Hyunsoo Hwang, Ilana Y Epstein, Dimitra Rafailia Bakaloudi, Rafee Talukder, Christopher J Hoimes

Oncologist· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
Antoni Ribas, Mohammed M Milhem, Christopher J Hoimes, Asim Amin, Christopher D Lao

Clin Cancer Res· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-Related Adverse Events and Associated Outcomes in Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin: Analysis of the UNITE Study.
Amanda Nizam, Charles B Nguyen, Jinju Li, Emily C Zabor, Pavlos Msaouel, Christopher J Hoimes

Cancer Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study.
Tanya Jindal, Cindy Y Jiang, Omar Alhalabi, Charles B Nguyen, Eugene Oh, Christopher J Hoimes

Eur Urol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
Julie N Graff, Christopher J Hoimes, Winald R Gerritsen, Ulka N Vaishampayan, Tony Elliott

Prostate Cancer Prostatic Dis· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor mutational burden as a marker for radiologic response to immune checkpoint inhibitors.
Dheeman Futela, Sree Harsha Tirumani, Ezgi Guler, Brandon Declouette, Christopher Hoimes

Curr Probl Diagn Radiol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
Kathryn E Beckermann, Neil J Shah, Matthew T Campbell, Naomi B Haas, Ariel Nelson, Christopher J Hoimes

Oncologist· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
John P Sfakianos, Arnab Basu, George Laliotis, Shivaram Cumarasamy, Jordan M Rich, Christopher J Hoimes

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.
Tanya Jindal, Cindy Jiang, Omar Alhalabi, Amanda Nizam, Charles Nguyen, Christopher Hoimes

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recognition and management of adverse cutaneous reactions in patients on enfortumab vedotin and pembrolizumab in the inpatient setting.
Emma L Myers, Jessica Liu, Sabrina M Shearer, Sarah A Myers, Michelle Schneider, Christopher Hoimes

JAAD Case Rep· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onco-Primary Care of Patients Receiving Immune Checkpoint Inhibitors.
Christopher J Hoimes, Suzanne McGettigan, Lee Schwartzberg

Am J Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Pavlos Msaouel, Randy F Sweis, Manojkumar Bupathi, Elisabeth Heath, Oscar B Goodman, Christopher J Hoimes

Eur Urol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
Kylie Fletcher, Alessio Cortellini, Teja Ganta, Roma Kankaria, Haocan Song, Christopher Hoimes

Cancer Lett· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-Dose Intravenous Vitamin C Combined with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer: A Randomized Placebo-Controlled Phase II Trial.
Channing J Paller, Marianna L Zahurak, Adel Mandl, Nicole A Metri, Aliya Lalji, Christopher Hoimes

Cancer Res Commun· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoural immunotherapy plus focal thermal ablation for localized prostate cancer.
Denis Séguier, Eric S Adams, Srinath Kotamarti, Vincent D'Anniballe, Zoe D Michael, Christopher Hoimes

Nat Rev Urol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Matthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, Daniel P Petrylak, Thomas W Flaig

J Clin Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen

Future Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the utility of molecular diagnostic classification for cancers of unknown primary.
Elle C Moore, Gerard C Blobe, Nicholas C DeVito, Brent A Hanks, Michael R Harrison, Christopher J Hoimes

Cancer Med· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.
Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig

J Clin Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of Antineoplastic Immunotherapy at a Large Healthcare Organization: Impact of Provider, Race and Socioeconomic Status.
Matthew M Mirsky, Carley Mitchell, Augustine Hong, Shufen Cao, Pingfu Fu, Christopher Hoimes

Cancer Manag Res· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.
Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.
Rafee Talukder, Dimitrios Makrakis, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Christopher J Hoimes

Clin Genitourin Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minding the Bathwater: Fertility and Reproductive Toxicity in the Age of Immuno-Oncology.
Anne E Kim, Ariel Nelson, Kyle Stimpert, Rebecca L Flyckt, Nannan Thirumavalavan, Christopher J Hoimes

JCO Oncol Pract· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Dimitrios Makrakis, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N Diamantopoulos, Scott Dawsey, Christopher J Hoimes

Clin Genitourin Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.
Rafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, Lucia Carril-Ajuria, Daniel Castellano, Christopher J Hoimes

Clin Genitourin Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis